R.PR
REGISTERED-PRINCIPAL REGISTER
01/11/2022
Back to search
Official data from USPTO
TPU PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
01/11/2022
Trademark type
Combined
Nice classes
3
Filing date
11/20/2018
Registration date
01/11/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/11/2022
Last transaction
01/11/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/19/2021
First use in commerce
04/19/2021
Drawing code
3
Owner type
03
Owner location
San Jose, CA, US
Examiner
OPUTA, CHIOMA N
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "TPU PHARMA" with each letter in "TPU" accented with one solid square. To the right of the wording "TPU" is the word "PHARMA" which is accented with an overline and an underline.
Holders and representatives
Holders
Teikoku Pharma USA, Inc.
Representatives
Bret E. Field BOZICEVIC, FIELD & FRANCIS LLP
Technical classification
Nice Classes
Class 3
Vienna Codes
No Vienna codes available.
Goods and services
Class 3
Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; non-medicated soaps for personal use; perfumery; essential oils; hair lotion
Publications
History of USPTO decisions and trademark events.
41 publications found
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/09/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/05/2021
ALIE
ASSIGNED TO LIE
11/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/28/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/06/2021
GNRT
NON-FINAL ACTION E-MAILED
08/06/2021
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/06/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/02/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/01/2021
IUAF
USE AMENDMENT FILED
06/22/2021
EISU
TEAS STATEMENT OF USE RECEIVED
06/22/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/23/2020
EX3G
SOU EXTENSION 3 GRANTED
12/21/2020
EXT3
SOU EXTENSION 3 FILED
12/21/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/21/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/24/2020
EX2G
SOU EXTENSION 2 GRANTED
06/22/2020
EXT2
SOU EXTENSION 2 FILED
06/22/2020
EEXT
SOU TEAS EXTENSION RECEIVED
06/22/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/20/2019
EX1G
SOU EXTENSION 1 GRANTED
12/18/2019
EXT1
SOU EXTENSION 1 FILED
12/18/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/18/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/25/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/30/2019
PUBO
PUBLISHED FOR OPPOSITION
04/30/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/10/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/23/2019
ALIE
ASSIGNED TO LIE
03/23/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/04/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/04/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/04/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
03/04/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/04/2019
DOCK
ASSIGNED TO EXAMINER
02/23/2019
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/08/2018
NWAP
NEW APPLICATION ENTERED
11/23/2018
Continuous trademark protection
Get notified about every new filing that threatens TPU PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.